Discovery of imidazole carboxamides as potent and selective CCK1R agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 15, 2008, Pages 4393-4396

  Zhu, Cheng ^a   Hansen, Alexa R ^a   Bateman, Thomas ^a   Chen, Zhesheng ^a   Holt, Tom G ^a   Hubert, James A ^a   Karanam, Bindhu V ^a   Lee, Susan J ^a   Pan, Jie ^a   Qian, Su ^a   Reddy, Vijay B G ^a   Reitman, Marc L ^a   Strack, Alison M ^a   Tong, Vincent ^a   Weingarth, Drew T ^a   Wolff, Michael S ^a   MacNeil, Doug J ^a   Weber, Ann E ^a   Duffy, Joseph L ^a   Edmondson, Scott D ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

1,2 Diaryl imidazole; CCK1R agonist; Cholecystokinin; Food intake reduction; Obesity

Indexed keywords

CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; IMIDAZOLECARBOXAMIDE;

ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; FOOD INTAKE; GALLBLADDER EMPTYING; STRUCTURE ACTIVITY RELATION;

AMIDES; ANIMALS; ANTI-OBESITY AGENTS; COMBINATORIAL CHEMISTRY TECHNIQUES; EATING; GALLBLADDER EMPTYING; HUMANS; IMIDAZOLES; MICE; MOLECULAR STRUCTURE; RECEPTORS, CHOLECYSTOKININ; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 47749126115     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.06.057     Document Type: Article

References (21)

1. Wank S.A. Am. J. Physiol. 274 (1998) G607
2. Gibbs J., Young R.C., and Smith G.P. J. Comp. Physiol. Psychol. 84 (1973) 488
3. For recent reviews see. Little T.J., Horowitz M., and Feinle-Bisset C. Obes. Rev. 6 (2005) 297
4. Moran T.H., and Kinzig K.P. Am. J. Physiol. Gastrointest. Liver Physiol. 286 (2004) G183
5. Chandra R., and Little T.J. Curr. Opin. Endocrinol. Diabetes Obes. 14 (2007) 63
6. Dufresne M., Seva C., and Fourmy D. Physiol. Rev. 86 (2006) 805
7. For lead CCK1R medicinal chemistry reviews see. Szewczyk J.R., and Laudeman C. Curr. Top. Med. Chem. 3 (2003) 837
8. Garci{dotless}́a-López M.T., González-Mu ñiz R., Marti{dotless}́n-Marti{dotless}́nez M., and Herranz R. Curr. Top. Med. Chem. 7 (2007) 1180
9. Jordan J., Greenway F.L., Leiter L.A., Li Z., Jacobson P., Murphy K., Hill J., Kler L., and Aftring R.P. Clin. Pharmacol. Ther. 83 (2008) 281
10. Castillo E.J., Delgado-Aros S., Camilleri M., Burton D., Stephens D., O'Connor-Semmes R., Walker A., Shachoy-Clark A., and Zinsmeister A.R. Am. J. Physiol. Gastrointest. Liver Physiol. 287 (2004) G363
11. 50 values are human IP3 (NFAT) agonist data except in Table 6 which are mouse CCK1R IP3 data. Both CCK1 and CCK2 % activation are expressed as the % of activation relative to CCK-8. Additional assay protocols are given in Supporting Information.
12. A series of 1,2-diary imidazoles have recently been reported as CCK1R antagonists:. McClure K., Hack M., Huang L., Sehon C., Morton M., Li L., Barrett T.D., Shankley N., and Breitenbucher J.G. Bioorg. Med. Chem. Lett. 16 (2006) 72
13. Sehon C., McClure K., Hack M., Morton M., Gomez L., Li L., Barrett T.D., Shankley N., and Breitenbucher J.G. Bioorg. Med. Chem. Lett. 16 (2006) 77
14. Gomez L., Hack M.D., McClure K., Sehon C., Huang L., Morton M., Li L., Barrett T.D., Shankley N., and Breitenbucher J.G. Bioorg. Med. Chem. Lett. 17 (2007) 6493
15. Lange J.H.M., van Stuivenberg H.H., Coolen H.K.A.C., Adolfs T.J.P., McCreary A.C., Keizer H.G., Wals H.C., Veerman W., Borst A.J.M., de Looff W., Verveer P.C., and Kruse C.G. J. Med. Chem. 48 (2005) 1823
16. Ueki H., Ellis T.K., Martin C.H., Boettiger T.U., Bolene S.B., and Soloshonok V.A. J. Org. Chem. 68 (2003) 7104
17. Old D.W., Wolfe J.P., and Buchwald S.L. J. Am. Chem. Soc. 120 (1998) 9722
18. CCK2R % activation and CCK2R % inhibition at 10,000 nM data for compounds 38-50 are given in Supporting Information.
19. No distinguishable behavioral features were noted between treatment and vehicle control groups of the ONFI mice at both administered doses (0.3 and 3 mg/kg). Subsequent manuscripts describing the in vivo characteristics (tolerability and efficacy) are in preparation.
20. Kopin A.S., Mathes W.F., McBride E.W., Nguyen M., Al-Haider W., Schmitz F., Bonner-Weir S., Kanarek R., and Beinborn M. J. Clin. Invest. 103 (1999) 383
21. Sugg E.E., Birkemo L., Gan L.-S.L., and Tippin T.K. Pharm. Biotechnol. 11 (1998) 507